If you are having thoughts of suicide right now, please reach out for immediate support. In the U.S., you can call or text 988 to reach the Suicide and Crisis Lifeline, 24 hours a day. If you or someone else is in immediate danger, call 911 or go to the nearest emergency room. Spravato is a scheduled, in-clinic treatment; it is not an emergency service and is not a substitute for crisis care.
With that said, many people are surprised to learn that Spravato (esketamine) has a second FDA-approved use specifically related to depression with suicidal thoughts. This article explains what that indication is, what it is and is not, and how it fits alongside crisis and hospital care. It is patient education, not medical advice.
Spravato’s second FDA indication, explained
Most people know Spravato for treatment-resistant depression. It also carries a second, separate FDA-approved indication. According to the label, Spravato is indicated for:
“Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.”
This is sometimes called the MDSI indication (major depressive disorder with suicidal ideation or behavior). A few things stand out in that wording. It is for adults with major depressive disorder who are experiencing acute suicidal ideation or behavior, and it is used in conjunction with an oral antidepressant — not on its own. That differs from the treatment-resistant depression indication, which the 2025 label allows to be used “as monotherapy or in conjunction with an oral antidepressant.”
You can read a plain-language overview of Spravato’s approved uses on our what Spravato is used for page and background on the medication itself on our what is Spravato page.
What this indication is — and what it is not
This is the most important part of the article, and the label is explicit about it. Under its Limitations of Use, the prescribing information states:
“The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO.”
Read that carefully, because it matters. Spravato is not proven to prevent suicide or to reduce suicidal thoughts or behavior. Its approval in this setting is for depressive symptoms in people who have acute suicidal ideation or behavior — and it does not replace the need for hospitalization or emergency care when that is clinically appropriate, even if someone feels better after a first dose.
In other words, Spravato can be one part of a comprehensive plan for a person in acute distress, but it is not a crisis intervention by itself, and it does not change the fact that acute safety may require hospital-level care. That decision belongs to the treating clinicians who are evaluating the person in real time.
How it fits with hospital and crisis care
Because this indication involves acute suicidal ideation or behavior, it is typically considered as part of care coordinated with a broader treatment team, which may include emergency evaluation, hospitalization, safety planning, therapy, and ongoing psychiatric care. The evidence supporting this use came from short-term studies; the label notes that “treatment beyond 4 weeks has not been systematically evaluated” for this indication, and that after four weeks of treatment, evidence of benefit should be evaluated to determine whether continued treatment is needed.
The practical takeaway: if you or someone you love is in acute crisis, the first step is immediate safety, not scheduling an outpatient treatment. Spravato may enter the conversation as part of a longer-term plan once a person is stabilized and under the care of a clinical team.
Where NeuroGlow fits in
NeuroGlow is an outpatient, REMS-certified Spravato provider with three Dallas–Fort Worth locations in Fort Worth, McKinney, and Flower Mound, led by Dr. Aaron Brown, DO. We are not an emergency or crisis facility. Our role is in ongoing, scheduled care: after a person is stabilized and working with a clinical team, we can evaluate whether Spravato is an appropriate part of their depression treatment, coordinate with their providers, and administer it safely under the required monitoring.
If you are exploring Spravato for yourself or a loved one as part of a longer-term plan, our first Spravato appointment guide explains what to expect, and our is Spravato safe page covers the monitoring and safety program.
Again, if you are in crisis right now, call or text 988, or call 911. Please reach out — support is available, and you deserve it.
Talk with our team about long-term care
If the immediate crisis has passed and you want to understand whether Spravato could be part of an ongoing plan, we are here to help you think it through. Book a free Spravato consultation with NeuroGlow, or call us at 469-218-4410. For any acute emergency, please use 988 or 911 rather than waiting for an appointment.
This is a sensitive topic. If you are struggling, you are not alone, and reaching out for help is a sign of strength.
Frequently asked questions
Does Spravato prevent suicide?
No. The Spravato label states that its “effectiveness in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated.” Its second FDA indication is for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior, used together with an oral antidepressant — not as a treatment proven to stop suicidal thoughts.
What is the MDSI indication for Spravato?
It is the label’s indication for “depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.” It is used alongside an oral antidepressant and does not replace emergency or hospital care when that is needed.
Can Spravato replace hospitalization in a crisis?
No. The label states that “use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose.” Acute safety decisions are made by the treating clinicians. If you are in crisis, call or text 988 or call 911.
Is Spravato used alone for this indication?
No. For the depression-with-acute-suicidal-ideation indication, Spravato is used in conjunction with an oral antidepressant, according to the label.
Is NeuroGlow an emergency or crisis service?
No. NeuroGlow is an outpatient, REMS-certified Spravato clinic. We provide scheduled, ongoing care and coordinate with your treatment team. For emergencies or acute crises, call or text 988 or call 911.
I’m supporting a loved one who is stabilized. Can Spravato help long-term?
It may be appropriate as part of a longer-term depression plan once a person is stabilized and under clinical care. The best next step is a consultation where our team can review their history and coordinate with their providers.
If depression with suicidal thoughts is part of your story — or a loved one’s — you don’t have to figure out the next step alone. Spravato is FDA-approved for depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or actions, used together with an oral antidepressant, and our team is glad to talk through whether an evaluation makes sense. Book a free Spravato consultation or call us at 469-218-4410.
If you are in crisis right now, please don’t wait for an appointment: call or text 988, or call 911.
